• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CureVac

News headline image
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
July 05, 2022
From CureVac
Via AccessWire
Topics Intellectual Property Lawsuit
Tickers CVAC
News headline image
CureVac Announces Voting Results of General Meeting
June 22, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
June 08, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
June 08, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
May 25, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
May 25, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
April 28, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
April 22, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
April 21, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
April 11, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
March 30, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
March 01, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
February 10, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
January 17, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
November 19, 2021
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
November 18, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
November 10, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
October 12, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Streamlines European Network for mRNA Product Manufacturing
September 14, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
August 31, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
August 30, 2021
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
August 16, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
August 16, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
June 30, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
June 30, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Announces Voting Results of General Meeting
June 25, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Provides Supervisory Board Update
June 23, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Appoints Klaus Edvardsen as Chief Development Officer
June 02, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
May 28, 2021
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap